Related Suggestion
There are an estimated 1 billion flu cases annually around the world according to WHO. Giving the early symptoms manifested by flu and COVID-19 are similar, tests for differentiation will be significant to enable accurate diagnosis and treatment. With the possible COVID-19 resurgence in winter, demands for flu and COVID-19 testing will be jumped high in parallel.
Health authorities and Dx companies already rolled out strategies and products in preparation for increasing needs of flu and COVID-19 testing. The Department of Health and Social Care of the UK has deployed new multiplex tests to differentiate flu and COVID-19 in hospitals, care houses, and labs since mid-August. Several companies introduced FDA and CE-cleared multiplex test panels for SARS-CoV-2, flu A/B, and RSV. Companies in the US aim to double testing capacity to serve millions of people who will line up for testing flu and COVID-19. Testing providers such as Fulgent Genetics offers influenza A/B test results to patients who test for COVID-19 throughout the winter.
However, current multiplex tests for flu and COVID-19 are mostly based on RT-PCR technology, which has disadvantages of cost, detection time and requirement of laboratory settings. Therefore, pushing combo Flu/COVID-19 test kits that can be performed directly in clinics and surveillant areas can unlock new business opportunities.
Product Features
-
Validated by the NIBSC & newly released China CDC influenza panels
-
Excellent reactivity & specificity
-
No cross-reaction to other respiratory diseases
*NIBSC refers to The National Institute for Biological Standards and Control that supplies international biological standards and other biological reference materials to WHO for influenza test standardization. China CDC refers to the Chinese Center for Disease Control and Prevention
Featured Antibody Pairs (Lateral Flow Platform)
Product |
Pair No. |
Catalog No. |
Source |
Clone |
Isotype |
Application |
Blocker |
Influenza A |
Pair 1 |
BRCINFS102 |
CHO |
31B4 |
IgG1 |
Coating |
√ |
BRJINFS102 |
CHO |
30C6 |
IgG2a |
Conjugate |
√ |
||
Pair 2 |
BRJINFS102 |
CHO |
30C6 |
IgG2a |
Coating |
√ |
|
BRCINFS102 |
CHO |
31B4 |
IgG1 |
Conjugate |
√ |
||
Pair 3 |
BRCINFS103 |
CHO |
30A5 |
IgG2a |
Coating |
√ |
|
BRCINFS102 |
CHO |
31B4 |
IgG1 |
Conjugate |
√ |
||
Influenza B |
Pair 1 |
BRNINFJ203 |
CHO |
30D4 |
IgG2a |
Coating |
√ |
BRNINFC202 |
CHO |
30E3 |
IgG1 |
Conjugate |
√ |
||
Pair 2 |
BRNINFC201 |
Mouse |
2F3 |
IgM |
Coating |
√ |
|
BRNINFJ204 |
CHO |
30E2 |
IgG2b |
Conjugate |
√ |
||
Pair 3 |
BRNINFJ203 |
CHO |
30D4 |
IgG2a |
Coating |
√ |
|
BRNINFC201 |
Mouse |
2F3 |
IgM |
Conjugate |
√ |
Performance
Reactivity-Influenza A Antibody Pairs
Sample Info |
Reactivity |
|||||
Source |
Type of Virus |
Viral Strain |
Dilution Ration |
Pair 1 |
Pair 2 |
Pair 3 |
Fapon Quality Control |
Cultured-based Virus |
H1N1 |
1:500 |
C2 |
C3+ |
C3+ |
1:5000 |
C5+ |
C5 |
C5 |
|||
1:50000 |
C7 |
C8+ |
C8+ |
|||
H3N2 |
1:500 |
C1 |
C1 |
C1 |
||
1:5000 |
C3 |
C3 |
C3 |
|||
1:50000 |
C5+ |
C5 |
C5 |
|||
H5N1 |
1:20 |
C2 |
C3+ |
C3+ |
||
1:200 |
C6+ |
C6 |
C6 |
|||
1:2000 |
C8+ |
C9+ |
C9+ |
|||
H7N9 |
1:20 |
C2+ |
C2 |
C2 |
||
1:200 |
C5+ |
C5 |
C5 |
|||
1:2000 |
C7 |
C8 |
C8 |
|||
NIBSC Standard |
Inactivated Virus |
Influenza Virus Infectious NYMC X-185 |
20 |
C1+ |
C1+ |
C1+ |
1000 |
C6 |
C7 |
C7 |
|||
Influenza Virus infectious Resvir-14 (H3N2) |
20 |
C2 |
C3 |
C3 |
||
1000 |
C8 |
C9 |
C9 |
|||
Influenza Virus infectious NIB-26 (H3N2) |
20 |
C2+ |
C2 |
C2 |
||
1000 |
C7 |
C9+ |
C9+ |
|||
Influenza Antigen A/Texas/50/2012 (NYMC X-223A) |
20 |
C6 |
- |
- |
||
1000 |
C9+ |
C9+ |
C9+ |
|||
Influenza Virus infectious A/Beijing/32/92 (H3N2) |
20 |
C1 |
C2+ |
C2+ |
||
1000 |
C7 |
C8+ |
C8+ |
|||
Influenza Virus infectious A/Shanghai/24/90 |
20 |
C1 |
C2 |
C2 |
||
1000 |
C7 |
C8 |
C8 |
|||
Influenza Virus infectious A/Sichuan/346/98 (H3N2) |
20 |
C1 |
C1 |
C1 |
||
1000 |
C8+ |
C8 |
C8 |
|||
Others |
2019/H3N2 |
20 |
C1 |
C2+ |
C2+ |
|
2019/H1N1 |
20 |
C1 |
C2 |
C2 |
||
2019/H1N1 |
20 |
C1 |
C1 |
C1 |
||
A/Brisbane/10/2007 |
- |
Detectable |
||||
A/Perth/16/2009 |
||||||
A/California/7/2004 |
||||||
A/Brisbane/59/2007 |
||||||
A/Victoria/361/2011 |
||||||
A/California/7/2009 |
||||||
A/New Caledonia/20/1999 |
||||||
A/Wisconsin/67/2005 |
||||||
A/Solomon Islands/3/2006 |
||||||
H1N1 Virus |
A/Taiwan/1/86(8IN73) |
|||||
A/Beijing/262/95(8IN73-2) |
||||||
Influenza Virus infectious A/Guizhou/54/89 (H3N2) |
||||||
Influenza Virus infectious A/Wuhan/359/95 (H3N2) |
||||||
H3N2 Virus |
A/Victoria/210/2009w |
|||||
A/Kiev/301/94(8IN74-2) |
||||||
H3N2 A/Panama/2007/998IN74-1 |
||||||
A/Shandong/9/93(8IN74) |
||||||
A/Texas/50/2012 |
||||||
A/Hiroshima/52/2005 |
Reactivity-Influenza B Antibody Pairs
Sample Info |
Reactivity |
|||||
Source |
Type of Virus |
Viral Strain |
Dilution Ration |
Pair 1 |
Pair 2 |
Pair 3 |
Fapon Quality Control |
Cultured-based Virus |
Influenza B Quality Control |
30 |
C4 |
C4+ |
C4 |
300 |
C6 |
C6+ |
C6 |
|||
3000 |
C8 |
C8+ |
C8 |
|||
NIBSC Standard |
Inactivated Virus |
Influenza Virus infectious NYMC BX-7 |
20 |
C4 |
C4+ |
C4+ |
1000 |
C9 |
C9 |
C9 |
|||
Influenza virus infectious NYMC BX-39 |
20 |
C3 |
C3+ |
C3 |
||
1000 |
C8+ |
C8+ |
C8+ |
|||
Others |
BY-V1908875256 |
32 |
C4 |
C3 |
C4+ |
|
640 |
C6 |
C5 |
C6+ |
|||
BV-V1906106179 |
64 |
C5 |
C5+ |
C5 |
||
640 |
C7 |
C7+ |
C7 |
|||
BV-V1906106180 |
100 |
C7 |
C7 |
C7 |
||
1000 |
C9 |
C9 |
C9 |
|||
BV-V1906106181 |
100 |
C6 |
C7 |
C7 |
||
1000 |
C8 |
C9 |
C9 |
|||
BV-V1906106182 |
100 |
C5 |
C6+ |
C6 |
||
1000 |
C8 |
C8 |
C8 |
|||
B/Shanghai/361/02 |
- |
Detectable |
||||
B/Malaysia/2506/2004 |
||||||
B/Massachusetts/2/2012 |
||||||
B/Wisconsin/01/2010 |
||||||
B/Tokio/53/99 |
||||||
Influenza Virus infectious B/Sichuan/379/99 |
||||||
B/Qingdao/102/91 |
||||||
B/Brisbane/60/2008 |
||||||
B/Florida/04/2006 |
||||||
B/Victoria/504/00 |
||||||
Influenza Virus infectious B/Shanghai/361/2002 |
Result interpretation: the higher the number, the lower the activity, B refers to undetectable
Cross-Reactivity
Tested Fapon Influenza A/B antibodies with SARS-CoV-2, Mycoplasma Pneumoniae, Parainfluenza, RSV, Adenovirus and other viral pathogens at different concentrations, results showed no detection, suggesting no cross-reaction and false-positive results.
Type of Pathogen |
Pathogen |
Type of Virus |
Concentration |
Result |
SARS-CoV-2 |
S/ N Protein |
Recombinant antigen |
10 μg/mL |
No cross-reaction with Influenza A/B |
Cultured-based virus |
1:200 Dilution |
|||
Mycoplasma Pneumoniae |
Mycoplasma pneumonia |
Inactivated virus |
50 μg/mL |
|
Parainfluenza |
Parainfluenza 2 |
5 μg/mL |
||
RSV |
RSV |
50 μg/mL |
||
Adenovirus |
Adenoviridae |
10 μg/mL |
||
Influenza B |
Influenza B virus |
Cultured-based virus |
55 μg/mL |
No cross-reaction with Influenza |
Influenza A H1N1 |
Influenza A virus |
2 μg/mL |
No cross-reaction with Influenza A |
|
Influenza A H3N2 |
36 μg/mL |
|||
Influenza A H5N1 |
15 μg/mL |
|||
Influenza A H7N9 |
40 μg/mL |
|||
Others |
EB virus |
Inactivated virus |
30 μg/mL |
No cross-reaction with Influenza A/B |
Mumps virus |
50 μg/mL |
|||
Varicella-zoster virus |
50 μg/mL |
|||
Human cytomegalovirus |
1:10 Dilution |
|||
Measles virus |
1:10 Dilution |
|||
Rotavirus |
1:10 Dilution |
Specificity
Tested Fapon Influenza A & B Antibody Pairs and Combo (Influenza A Pair 1 + Influenza B Antibody Pair 2) respectively with 106 clinical throat swab samples, results showed 100% specificity, no false-positive results.
Stability
Fapon Influenza Antibody Pairs showed little changes in activity and specificity levels in different temperature, storage periods, and repeated freezing/thawing at 18 times, confirming excellent product stability.
Temperature (C°) |
Evaluation Period (Days) |
-80 |
21 |
-20 |
21 |
-4 |
21 |
Room Temperature |
7/14/21 |
37 |
7/14/21 |
45 |
7 |